Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

70 questions · 70 findings · 12 reviews · Gynaecological, Neuro-oncology and Orphan Cancer · Headline outcomes only

No studies found 18 · 25.7%GRADE not reported 3 · 4.3%Very low 19 · 27.1%Low 16 · 22.9%Moderate 10 · 14.3%High 4 · 5.7%

Early discontinuation of antibiotic treatment vs treatment until neutropenia resolution

All‐cause mortality · febrile neutropenia

Early discontinuation of antibiotic treatment showed no clear difference in mortality compared with treatment until neutropenia resolution (low certainty).

1 finding from 1 review

Early discontinuation of antibiotic treatment vs treatment until neutropenia resolution

Clinical failure · febrile neutropenia

It is very uncertain whether early discontinuation of antibiotic treatment changes clinical failure compared with treatment until neutropenia resolution (very low certainty).

1 finding from 1 review

Early discontinuation of antibiotic treatment vs treatment until neutropenia resolution

Bacteraemia · febrile neutropenia

It is very uncertain whether early discontinuation of antibiotic treatment changes any bacteraemia compared with treatment until neutropenia resolution (very low certainty).

1 finding from 1 review

Laparoscopy vs laparotomy

Overall survival (survival until death from all causes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.

Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).

1 finding from 1 review

Laparoscopy vs laparotomy

Serious adverse events (range of outcomes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.

Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).

1 finding from 1 review

Intervention not reported

Death from all causes · patients with early stage cervical cancer

The intervention probably leads to lower death from all causes (moderate certainty).

1 finding from 1 review

Intervention not reported

Disease progression · patients with early stage cervical cancer

The intervention probably leads to lower disease progression (moderate certainty).

1 finding from 1 review

Intervention not reported

Grade 4 toxicity3 · patients with early stage cervical cancer

The intervention probably leads to higher grade 4 toxicity3 (moderate certainty).

1 finding from 1 review

Intervention not reported

Disease progression · patients with early stage cervical cancer

The intervention showed no clear difference in disease progression (low certainty).

1 finding from 1 review

Intervention not reported

Death within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)

The intervention showed no clear difference in death within 5 years (moderate certainty).

1 finding from 1 review

Intervention not reported

Disease progression within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)

The intervention probably leads to lower disease progression within 5 years (moderate certainty).

1 finding from 1 review

Intervention not reported

Haematological adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)

The intervention showed no clear difference in haematological adverse events (grade 3 or 4) (moderate certainty).

1 finding from 1 review

Intervention not reported

Gastrointestinal adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)

The intervention showed no clear difference in gastrointestinal adverse events (grade 3 or 4) (moderate certainty).

1 finding from 1 review

Intervention not reported

Genitourinary adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)

The intervention showed no clear difference in genitourinary adverse events (grade 3 or 4) (moderate certainty).

1 finding from 1 review